Clinical Trials Logo

Supportive Care clinical trials

View clinical trials related to Supportive Care.

Filter by:
  • Terminated  
  • Page 1

NCT ID: NCT03924557 Terminated - Chemotherapy Clinical Trials

Genotype-guided Supportive Care in Symptom Treatment of Cancer Patients

Start date: July 9, 2019
Phase: N/A
Study type: Interventional

Cancer patients often require administration of multiple supportive care pharmacotherapies while receiving chemotherapy regardless the type of cancer. Supportive care therapies are commonly prescribed to nearly all cancer patients and could include antiemetics (ondansetron), pain management (opiates), GI protection (PPIs), antidepressants (select SSRIs), anticoagulation (warfarin) and antifungal prophylaxis (voriconazole). These are all are associated with known pharmacogenetic interactions, which in some cases render the drugs ineffective or toxic. This could result in negative impacts on quality of life in patients who are already undergoing complicated and costly anticancer regimens. Pharmacogenetic-guided therapy based on an individual patient's genetic profile could potentially target symptoms for which an individual is uniquely susceptible, guiding use of medications that are most likely to be effective, thereby reducing unnecessary physical complications and financial strain. It is hypothesized that patients in the genotype intervention arm will report lower scores for overall symptom distress as compared to patients in the delayed genotype intervention arm following initiation of chemotherapy.

NCT ID: NCT02581059 Terminated - Colorectal Cancer Clinical Trials

Efficacy of Ginseng for Patients on Regorafenib

Start date: April 2016
Phase: Phase 2
Study type: Interventional

This is a randomized, multi-center phase II study of ginseng in colorectal cancer patients treated with regorafenib to determine if ginseng will reduce fatigue in this patient population and improve adherence to regorafenib. Ninety (90) subjects will be enrolled and randomized using a 2:1 allocation, with 60 subjects enrolled in the regorafenib + ginseng group and 30 enrolled in the regorafenib + no ginseng group.